Breaking News

Tweet TWEET

BSD Medical Announces Egyptian Ministry of Health Marketing and Import License Approval for the MicroThermX® Microwave Ablation

  BSD Medical Announces Egyptian Ministry of Health Marketing and Import
  License Approval for the MicroThermX® Microwave Ablation System in Egypt and
  Shipment of Products to Distributor

Business Wire

SALT LAKE CITY -- May 29, 2014

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that BSD's exclusive distributor in Egypt, Misr Sinai, has
obtained marketing and import license approval for the MicroThermX^® Microwave
Ablation System (MicroThermX) from the Egyptian Ministry of Health. Misr Sinai
has purchased MicroThermX systems and antennas, and BSD recently shipped the
initial order to Misr Sinai.

Misr Sinai is a leading, medical, specialty distributor in Egypt with 130
employees, and revenues in excess of 18 million dollars. Their offices are
located in Cairo, Delta, and Alexandria. Misr Sinai represents a number of
major medical device companies and sells strategically adjacent products to
the same clinicians targeted for the MicroThermX.

BSD personnel provided intensive training of Misr Sinai sales personnel at the
2014 European Conference on Interventional Oncology (ECIO) in preparation for
the commercial launch in Egypt by Misr Sinai.

“We are excited to have the opportunity to start selling the MicroThermX in
Egypt,” stated Sam Maravich, VP of International Sales and Marketing for BSD.
“We have worked closely with Misr Sinai on the marketing approval process so
that we could capitalize on the market for the MicroThermX in Egypt.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

The press release contains forward-looking statements, which are subject to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements relate to the Company’s expectations
that its Taiwan distributor will receive necessary regulatory approvals in
Taiwan, the Company’s plans to sell its products in Taiwan and the Company’s
relationship with Linden Bioscience, Ltd., and other matters. Readers are
cautioned that these forward-looking statements are only expectations and
predictions and may differ materially from actual future events or results due
to a variety of risks and uncertainties, including, among other things, the
risk that necessary government approvals to sell the Company’s products in
Taiwan will not be obtained, demand for the Company’s products in Taiwan may
not materialize, the Company may not be able to produce products to meet the
demand, global economic conditions and uncertainties in the geopolitical
environment and other risk factors set forth in the Company’s most recent
reports on Form 10-K and Form 10-Q filed with the SEC. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company
undertakes no obligation to update the forward-looking statements contained in
this release, except as required by law.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
Fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.